AstraZeneca PLC (BVMF:A1ZN34)

Market Cap	1.52T
Revenue (ttm)	309.78B
Net Income (ttm)	50.09B
Shares Out	n/a
EPS (ttm)	32.08
PE Ratio	30.34
Forward PE	17.93
Dividend	1.39 (1.74%)
Ex-Dividend Date	Aug 7, 2025

Volume	97
Average Volume	2,883
Open	81.46
Previous Close	80.65
Day's Range	79.30 - 81.46
52-Week Range	61.90 - 84.71
Beta	0.17
RSI	53.59
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1ZN34

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD